BioSpace News Archive

“I wanted to create an improved way for people with tremors to write, eat or use hand tools,” said an inventor, from Lakewood, Colo., “so I invented the STEADY TOOL

Virginia Bio has elected five new members to their Board of Directors for a term of three years beginning January 1.

TraceLink, Inc., the world’s largest integrated digital supply network, providing real-time information sharing for better patient outcomes, today announced that, for the third consecutive year, Shabbir Dahod, president and CEO of TraceLink, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7 at 5 p.m. PST at the Westin St. Francis in San Francisco.

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the identification of predictive biomarkers for AsiDNA™, its first-in-class non-targeted DNA Damage Response (DDR) inhibitor, which enables personalized medicine approaches.

The first annual CES Pitch Competition to highlight technology creating social connection was announced today by the Consumer Technology Association (CTA) Foundation and AARP

“I desired a means to verify unknown civil war descendants of their deceased veterans and was also engaged in genealogy family research projects,” said an inventor from Bedford, Texas. “This inspired me to develop a means to verify an individual’s heritage.”

Company poised to lead market in 2019 for payer-provider collaboration technology augmented with accountable community networks to solve social determinants of health at scale

KromaTiD, Inc. announced today that it has been selected to present at the 2019 Biotech Showcase and investor conference. David P. Sebesta, KromaTiD’s Chief Commercial Officer, will provide a business and technology update.

Tivic Health Systems Inc. today announced that ClearUP Sinus Pain Relief, a first-in-class bioelectronic treatment for sinus pain due to allergic rhinitis (hay fever), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Amunix Pharmaceuticals Inc. today announced that it has entered into a licensing agreement with Merck for rights to develop therapeutics against an undisclosed target using Amunix’s proprietary protease-triggered immune activator (ProTIA) technology platform.